Press Release 2019 - Sami-Sabinsa Group | Formerly Known as Sami Labs Limited

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.

Sabinsa Named a Top New Jersey Company for Its Dynamic Growth

Sabinsa Issued New U.S. Patent for LactoSpore® Based upon Published Research Confirming Ability to Reverse Depression Symptoms in Patients Suffering from IBS

Sabinsa’s Pterostilbene in Silbinol® Subject of Published Study

Sabinsa’s Parent Dubbed Most Trusted Nutraceutical Company

Government of Karnataka State, India Recognizes the Sami- Sabinsa Group with Three Awards for Export Excellence

Research Finds Sabinsa’s Curcumin C3 Complex® in Combination with BioPerine® Effective for Non-Alcoholic Fatty Liver Disease

Certificates

Global Offices

Get in Touch

Disclaimer